Search results
Results From The WOW.Com Content Network
The Medicare Prescription Drug, Improvement, and Modernization Act, [1] also called the Medicare Modernization Act or MMA, is a federal law of the United States, enacted in 2003. [2] It produced the largest overhaul of Medicare in the public health program's 38-year history.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Following a periodic survey of an entity and a thorough investigation, the Centers for Medicare & Medicaid Services (CMS) or a state health agency acting on behalf of CMS may issue an immediate jeopardy warning (also called a notice, finding, or tag) to an entity. [2] The entity must immediately provide a plan of correction for the immediate ...
After a request comes in from a qualified provider, the request will go through the prior authorization process. The process to obtain prior authorization varies from insurer to insurer but typically involves the completion and faxing of a prior authorization form; according to a 2018 report, 88% are either partially or entirely manual.
The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The intent of the program is to allow covered entities to "stretch scarce federal resources as far as possible ...
Information about the 1-800-MEDICARE helpline from Medicare.gov, a 24X7 toll-free number where anyone can call with questions about the Part D benefit. Other resources "Medicare Part D Briefing Room", from the American Society of Consultant Pharmacists. "Medicare Prescription Drug Benefit Weekly Q&A Column", from the Kaiser Family Foundation.
Upgrade to a faster, more secure version of a supported browser. It's free and it only takes a few moments:
Detailed subheadings for each module are specified for all jurisdictions. The contents of Module 1 and certain subheadings of others differ based on national requirements. However, investigational new drugs meant for emergency use or treatment applications and not for commercial distribution are not subject to the CTD requirements. [5] [6]